Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy

Douglas B. Johnson, Erika K. Wallender, Daniel N. Cohen, Sunaina S. Likhari, Jeffrey P. Zwerner, Jennifer G. Powers, Lisa Shinn, Mark C. Kelley, Richard W Joseph, Jeffrey A. Sosman

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who were treated with anti-PD-1 agents as first-line therapy without significant toxicity, followed by vemurafenib at disease progression. Both patients developed severe hypersensitivity drug eruptions with multi-organ injury early in their BRAF inhibitor treatment course. One patient subsequently developed acute inflammatory demyelinating polyneuropathy (AIDP) and the other developed anaphylaxis upon low-dose vemurafenib rechallenge. Further investigation of the immune response during combination or sequences of melanoma therapeutics is warranted. Furthermore, clinicians should maintain a high index of suspicion for these toxicities when vemurafenib is administered following an anti-PD-1 agent.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalCancer immunology research
Volume1
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Nervous System
Melanoma
Skin
CD274 Antigen
Drug Eruptions
Guillain-Barre Syndrome
Anaphylaxis
Therapeutics
Disease Progression
Hypersensitivity
PLX4032
Wounds and Injuries

Keywords

  • anti-PD-1
  • immunotherapy
  • Melanoma
  • vemurafenib

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., ... Sosman, J. A. (2013). Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer immunology research, 1(6), 373-377. https://doi.org/10.1158/2326-6066.CIR-13-0092

Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. / Johnson, Douglas B.; Wallender, Erika K.; Cohen, Daniel N.; Likhari, Sunaina S.; Zwerner, Jeffrey P.; Powers, Jennifer G.; Shinn, Lisa; Kelley, Mark C.; Joseph, Richard W; Sosman, Jeffrey A.

In: Cancer immunology research, Vol. 1, No. 6, 01.12.2013, p. 373-377.

Research output: Contribution to journalArticle

Johnson, DB, Wallender, EK, Cohen, DN, Likhari, SS, Zwerner, JP, Powers, JG, Shinn, L, Kelley, MC, Joseph, RW & Sosman, JA 2013, 'Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy', Cancer immunology research, vol. 1, no. 6, pp. 373-377. https://doi.org/10.1158/2326-6066.CIR-13-0092
Johnson, Douglas B. ; Wallender, Erika K. ; Cohen, Daniel N. ; Likhari, Sunaina S. ; Zwerner, Jeffrey P. ; Powers, Jennifer G. ; Shinn, Lisa ; Kelley, Mark C. ; Joseph, Richard W ; Sosman, Jeffrey A. / Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. In: Cancer immunology research. 2013 ; Vol. 1, No. 6. pp. 373-377.
@article{4e9421e209b24b659cd913c6cb04d413,
title = "Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy",
abstract = "Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who were treated with anti-PD-1 agents as first-line therapy without significant toxicity, followed by vemurafenib at disease progression. Both patients developed severe hypersensitivity drug eruptions with multi-organ injury early in their BRAF inhibitor treatment course. One patient subsequently developed acute inflammatory demyelinating polyneuropathy (AIDP) and the other developed anaphylaxis upon low-dose vemurafenib rechallenge. Further investigation of the immune response during combination or sequences of melanoma therapeutics is warranted. Furthermore, clinicians should maintain a high index of suspicion for these toxicities when vemurafenib is administered following an anti-PD-1 agent.",
keywords = "anti-PD-1, immunotherapy, Melanoma, vemurafenib",
author = "Johnson, {Douglas B.} and Wallender, {Erika K.} and Cohen, {Daniel N.} and Likhari, {Sunaina S.} and Zwerner, {Jeffrey P.} and Powers, {Jennifer G.} and Lisa Shinn and Kelley, {Mark C.} and Joseph, {Richard W} and Sosman, {Jeffrey A.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0092",
language = "English (US)",
volume = "1",
pages = "373--377",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy

AU - Johnson, Douglas B.

AU - Wallender, Erika K.

AU - Cohen, Daniel N.

AU - Likhari, Sunaina S.

AU - Zwerner, Jeffrey P.

AU - Powers, Jennifer G.

AU - Shinn, Lisa

AU - Kelley, Mark C.

AU - Joseph, Richard W

AU - Sosman, Jeffrey A.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who were treated with anti-PD-1 agents as first-line therapy without significant toxicity, followed by vemurafenib at disease progression. Both patients developed severe hypersensitivity drug eruptions with multi-organ injury early in their BRAF inhibitor treatment course. One patient subsequently developed acute inflammatory demyelinating polyneuropathy (AIDP) and the other developed anaphylaxis upon low-dose vemurafenib rechallenge. Further investigation of the immune response during combination or sequences of melanoma therapeutics is warranted. Furthermore, clinicians should maintain a high index of suspicion for these toxicities when vemurafenib is administered following an anti-PD-1 agent.

AB - Immune checkpoint inhibitors such as ipilimumab and targeted BRAF inhibitors have dramatically altered the landscape of melanoma therapeutics over the past few years. Agents targeting the programmed cell death-1/ligand (PD-1/PD-L1) axis are now being developed and appear to be highly active clinically with favorable toxicity profiles. We report two patients with BRAF V600E mutant melanoma who were treated with anti-PD-1 agents as first-line therapy without significant toxicity, followed by vemurafenib at disease progression. Both patients developed severe hypersensitivity drug eruptions with multi-organ injury early in their BRAF inhibitor treatment course. One patient subsequently developed acute inflammatory demyelinating polyneuropathy (AIDP) and the other developed anaphylaxis upon low-dose vemurafenib rechallenge. Further investigation of the immune response during combination or sequences of melanoma therapeutics is warranted. Furthermore, clinicians should maintain a high index of suspicion for these toxicities when vemurafenib is administered following an anti-PD-1 agent.

KW - anti-PD-1

KW - immunotherapy

KW - Melanoma

KW - vemurafenib

UR - http://www.scopus.com/inward/record.url?scp=85006320672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006320672&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0092

DO - 10.1158/2326-6066.CIR-13-0092

M3 - Article

C2 - 24490176

AN - SCOPUS:85006320672

VL - 1

SP - 373

EP - 377

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 6

ER -